Novanta Earnings Call Transcripts
Fiscal Year 2026
-
The acquisition of Riverpoint Medical accelerates expansion into high-growth surgical consumables, is immediately accretive, and brings significant synergies and recurring revenue growth. The deal strengthens market position, leverages existing customer relationships, and sets a platform for future expansion.
-
Portfolio now over 50% medical, with reduced semiconductor exposure and strong focus on robotics, automation, and recurring revenue. Growth driven by innovation in medical consumables, intelligent subsystems, and GenAI-linked technologies, with double-digit growth targeted through organic and M&A strategies.
-
The meeting covered board introductions, review of 2025 financials, and voting on director elections, executive compensation, and auditor appointment. All proposals passed, and no shareholder questions were raised.
-
Q1 2026 saw double-digit bookings and revenue growth across all businesses, with strong cash flow and margin expansion despite tariff and cost headwinds. Guidance for 2026 was raised, supported by robust demand in AI, medical, and automation markets, and a strong acquisition pipeline.
Fiscal Year 2025
-
Record 2025 revenue and bookings, strong new product growth, and double-digit profit gains were achieved, though margins and cash flow were temporarily pressured by manufacturing transitions. 2026 guidance calls for 4–6% organic growth, margin expansion, and robust acquisition capacity.
-
Q3 2025 results exceeded expectations with record revenue, strong margin expansion, and robust new product growth. Guidance calls for sequential revenue and profit growth into Q4 and 2026, led by advanced surgery and robotics, with regional manufacturing and acquisitions supporting resilience.
-
Q2 2025 results met or exceeded expectations, with strong growth in advanced surgery and robotics, robust new product momentum, and major design wins. Guidance calls for 2–4% revenue growth in 2025, with ongoing tariff and trade risks but sequential improvement expected in industrial and life sciences.
-
Q1 2025 saw 2% organic revenue growth, strong cash flow, and robust new product launches, despite tariff headwinds and life science market weakness. Guidance for Q2 is $230M–$240M revenue, with EBITDA and EPS expected to remain solid.
Fiscal Year 2024
-
Solid 2024 results included record cash flow, margin expansion, and a return to organic growth in Q4. 2025 guidance targets 5% revenue growth, $50M in new product sales, and continued margin improvement, despite ongoing macro and geopolitical uncertainties.
-
Q3 2024 results were strong, with revenue at the high end of guidance and robust new product momentum. Near-term headwinds from customer shipment deferrals and macro uncertainty have shifted some revenue into 2025, but double-digit growth is expected in the second half of next year.
-
Q2 2024 results exceeded expectations for revenue, profit, and cash flow, driven by strong medical device demand and new product launches, despite ongoing weakness in life sciences and industrial markets. Full-year guidance was reaffirmed at the low end, with robust margin and cash flow outlook.